Haloperidol Richter

Haloperidol Richter is a prescription oral medication that contains the active ingredient haloperidol, a butyrophenone antipsychotic. It is marketed in the European Union and is supplied without a specified strength or dosage form in the available data. The product is intended for use under medical supervision for conditions that respond to dopamine D2 receptor antagonism. It belongs to ATC code N05AD01 and is classified as a prescription‑only drug.

Haloperidol Richter is indicated for several psychiatric and neurological conditions where dopamine blockade is therapeutic.

- Schizophrenia, including chronic and treatment‑resistant forms. - Acute psychotic episodes associated with mood disorders or substance use. - Mania episodes in bipolar disorder. - Tourette syndrome and other tic disorders. - Severe agitation requiring rapid control.

The medication may produce a range of adverse effects that are generally categorized by frequency and severity.

Common: - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Sedation or drowsiness. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort. - Weight gain or appetite changes.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction. - Tardive dyskinesia, characterized by involuntary movements. - Severe hypotension or cardiac arrhythmias. - Elevated prolactin levels leading to hormonal disturbances. - Agranulocytosis or other blood dyscrasias.

Clinicians should assess patient history and monitor for specific risks before and during treatment with Haloperidol Richter.

- History of cardiovascular disease or arrhythmias. - Pre‑existing movement disorders or Parkinsonian symptoms. - Liver or renal impairment affecting drug clearance. - Pregnancy, lactation, or potential teratogenic risk (category unknown). - Concomitant use of other central nervous system depressants. - Elderly patients, especially those with dementia‑related psychosis.

Haloperidol Richter can interact with other medicines, altering its effectiveness or increasing toxicity.

Avoid: - Other dopamine antagonists or antipsychotics that may amplify extrapyramidal effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels. - Medications known to prolong QT interval, increasing risk of cardiac arrhythmias.

Use with caution: - CYP3A4 inducers such as carbamazepine or rifampin, which may reduce drug exposure. - CNS depressants including benzodiazepines, opioids, or alcohol. - Anticholinergic agents that can mask extrapyramidal symptoms. - Antihypertensive drugs, as haloperidol may enhance hypotensive effects.